Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis

[1]  Y. Hiasa,et al.  Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study , 2022, Cancer medicine.

[2]  M. Kudo,et al.  Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. , 2022, European journal of cancer.

[3]  M. Kudo,et al.  Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, NEJM evidence.

[4]  J. Trojan,et al.  Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers , 2022, Cancers.

[5]  V. Velcheti,et al.  Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1 , 2022, Frontiers in Oncology.

[6]  Zachary J. Brown,et al.  Alteration in immune function in patients with fatty liver disease , 2022, Hepatoma Research.

[7]  M. Kudo,et al.  Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[8]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[9]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[10]  P. Galle,et al.  NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. , 2021, Journal of hepatology.

[11]  M. Kurosaki,et al.  Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice , 2021, Investigational New Drugs.

[12]  M. Colombo,et al.  Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  M. Kudo,et al.  Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience , 2021, Cancer reports.

[14]  C. Wong,et al.  The paradox of immunotherapy in NASH-HCC , 2021, Signal Transduction and Targeted Therapy.

[15]  Anala Gossai,et al.  Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States , 2021, Health services research.

[16]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[17]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[18]  M. Kudo,et al.  IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). , 2021, Journal of Clinical Oncology.

[19]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[20]  S. Ronnebaum,et al.  Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review , 2020, Hepatic oncology.

[21]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[22]  S. Baxi,et al.  Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR , 2020 .

[23]  G. Philip,et al.  Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data , 2020, PloS one.

[24]  Joshua Haimson,et al.  Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research , 2020, ArXiv.

[25]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Decaens,et al.  Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment , 2019, Cancers.

[27]  A. Abernethy,et al.  An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer , 2019, JCO clinical cancer informatics.

[28]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[29]  R. Bataller,et al.  Alcoholic liver disease , 2018, Nature Reviews Disease Primers.

[30]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[31]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[32]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[33]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[34]  R. Sun,et al.  Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances , 2017, Scientific Reports.

[35]  M. Kudo,et al.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications , 2017, Liver Cancer.

[36]  J. Marrero,et al.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.

[37]  M. Colombo,et al.  Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. , 2016, The lancet. Gastroenterology & hepatology.

[38]  J. Lund,et al.  Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma , 2016, The oncologist.

[39]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[41]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[42]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[43]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .